Approach to Hyponatremia
The management of hyponatremia should follow a systematic approach based on volume status assessment, severity of symptoms, and rate of sodium correction to prevent complications like osmotic demyelination syndrome. 1
Initial Assessment
Severity Classification
- Mild: 126-135 mEq/L (often asymptomatic)
- Moderate: 120-125 mEq/L (nausea, headache, confusion)
- Severe: <120 mEq/L (risk of seizures, coma, respiratory arrest) 1
Volume Status Assessment
Volume status is critical for determining the underlying cause and treatment approach:
| Volume Status | Clinical Signs | Urine Sodium | Likely Causes |
|---|---|---|---|
| Hypovolemic | Orthostatic hypotension, dry mucous membranes, tachycardia | <20 mEq/L | GI losses, diuretics, adrenal insufficiency |
| Euvolemic | No edema, normal vital signs | >20-40 mEq/L | SIADH, hypothyroidism, adrenal insufficiency |
| Hypervolemic | Edema, ascites, elevated JVP | <20 mEq/L | Heart failure, cirrhosis, renal failure |
Diagnostic Criteria for SIADH
- Hyponatremia (serum sodium < 134 mEq/L)
- Hypoosmolality (plasma osmolality < 275 mosm/kg)
- Inappropriately high urine osmolality (> 500 mosm/kg)
- Inappropriately high urinary sodium concentration (> 20 mEq/L)
- Absence of hypothyroidism, adrenal insufficiency, or volume depletion 3
Treatment Algorithm
Severe Symptomatic Hyponatremia (Seizures, Coma, Respiratory Distress)
Immediate intervention with 3% hypertonic saline:
Monitoring:
Moderate Symptomatic Hyponatremia
- Fluid restriction to 1-1.5 L/day for serum sodium <125 mmol/L 1
- Treatment based on volume status:
Mild to Moderate Asymptomatic Hyponatremia
- Address underlying cause (medication review, treat primary disease)
- Volume status-based approach:
Special Considerations
Tolvaptan Use
- Indication: Short-term treatment (≤30 days) for euvolemic or hypervolemic hyponatremia 6
- Starting dose: 15 mg once daily 1
- Monitoring: Watch for overly rapid correction and hypernatremia 6
- Caution: Avoid in patients with liver disease due to risk of liver injury 6
Cirrhosis-Related Hyponatremia
- For sodium levels 126-135 mmol/L with normal creatinine: Continue diuretic therapy with close electrolyte monitoring 1
- For sodium levels 121-125 mmol/L: Consider stopping diuretics 1
- For sodium levels <120 mmol/L: Stop diuretics and consider volume expansion 1
- Tolvaptan should be used cautiously as gastrointestinal bleeding was reported in 10% of cirrhotic patients vs. 2% in placebo group 6
Prevention of Osmotic Demyelination Syndrome
- Maximum correction rate: 8 mEq/L in 24 hours 1
- Risk factors: Chronic alcoholism, malnutrition, liver disease, hypokalemia 2
- If correction exceeds recommended rate, consider administering desmopressin and/or hypotonic fluids 4
Monitoring and Follow-up
- Frequent monitoring of serum sodium levels during active correction
- Continue monitoring after normalization to ensure stability
- Assess for neurological symptoms that might indicate osmotic demyelination syndrome
- Evaluate effectiveness of treatment of underlying conditions 1, 4
Remember that untreated severe hyponatremia carries a mortality rate of 25% compared to 9.3% when sodium levels are >120 mEq/L, highlighting the importance of prompt but careful management 1.